- Atorvastatin activates skeletal ryanodine receptors: Design of next-generation statins
C. Lindsay1,2, A. D. Wilson1, E. Venturi1, A. J. Russell1,2, R. Sitsapesan1. 1Department of Pharmacology, University of Oxford, Oxford, United Kingdom, 2Chemistry Research Laboratory, University of Oxford, Oxford, United Kingdom,
- Evidence that human P2Y1 and P2Y12 receptors form heterodimers
M. SAFAR. SIPBS, University of Strathclyde, Glasgow, United Kingdom,
- Expansion of the druggable genome in the IUPHAR/BPS Guide to PHARMACOLOGY and other drug target resources: a key substrate for future medicines
C. Southan,, J. L. Sharman, E. Faccenda, S. D. Harding, A. J. Pawson, J. A. Davies. Discovery Brain Sciences, Edinburgh University, Edinburgh, United Kingdom,
- Investigating SARMs as novel therapeutics in women
D. A. Gibson, I. Simitsidellis, O. Kelepouri, A. Esnal Zufiaurre, F. Collins, P. T. Saunders. MRC Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom,
- Modulation of angiotensin II signalling by cannabinoid receptor 1 antagonism in human coronary artery smooth muscle cells
W. AL ABDULLAH. Department of Cardiovascular Sciences,, university of leicester, leicester, United Kingdom,
- Non-invasive in human in vivo target engagement biomarkers to strengthen GO/NO-GO decisions
L. Buntinx1, L. Chang1, A. Amin1, M. Depr‚1, E. Ampe1, A. Vanhecken1, B. Morlion2, J. de Hoon1. 1Center for Clinical Pharmacology, UZ Leuven, Leuven, Belgium, 2The Leuven Centre for Algology & Pain Management, Leuven, Belgium,
- Novel synthetic superenhancers for drug screening in cancer stem cells
U. Koeber1,2, S. M. Pollard1,2. 1MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom, 2UK Centre for Mammalian Synthetic Biology, University of Edinburgh, Edinburgh, United Kingdom,
- Selective Interleukin-6 trans-signalling antagonism with sgp130Fc reduces infarct size in a rat model of myocardial infarction whereas pan-blockade with an anti-IL-6 antibody does not
M. J. George1, D. Stuckey2, N. H. Jasmin2, V. Taylor2, A. D. Hingorani3, D. Gilroy1. 1Clinical Pharmacology, University College London, London, United Kingdom, 2Centre For Advanced Biological Imaging, University College London, London, United Kingdom, 3Institute of Cardiovascular Science, University College London, London, United Kingdom,
- Sumoylation of the β2ARinfluences receptor internalisation, desensitisation and downstream signaling
J. Ling1, L. Wills2, G. Baillie1. 1Institute of Cardiovascular and Medical Science, Glasgow, United Kingdom, 2Cardiovascular research center mount sinai, New York,
- Surrogate outcomes supporting conditional marketing authorisations and accelerated approvals by the european medicines agency, 2011-2018
C. S. Schuster Bruce1, P. McGettigan1, P. Brhlikova2. 1William Harvey Research Institute, London, United Kingdom, 2Newcastle University, Newcastle, United Kingdom,